Floatz Rating
BBB76/100
Confidence
Indicative
Sponsor
Ege University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
77High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07242131CT.gov Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS | — | Recruiting | — | — | — |
NCT06852365CT.gov Combined Oral Contraceptive Pill and Resistance Starch | — | Recruiting | — | — | — |
NCT07318337CT.gov Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS | — | Completed | — | — | — |
NCT06889454CT.gov Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS | — | Recruiting | — | — | — |
NCT05021861CT.gov Evaluation of Periodontal Status and hsCRP Levels in Females With PCOS on CPA/EE Combination Drug Regimen | — | Unknown | — | — | — |
NCT04257500CT.gov Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS | — | Completed | — | — | — |
NCT03843736CT.gov The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS. | — | Unknown | — | — | — |
NCT03043924CT.gov Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS) | — | Completed | — | — | — |
NCT02866786CT.gov The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS | — | Completed | — | — | — |
NCT02027337CT.gov Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants | — | Unknown | — | — | — |
Show 9 more trialsShow fewer
NCT01573377CT.gov Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial | — | Completed | — | — | — |
NCT01360996CT.gov Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism | — | Completed | — | — | — |
NCT01459445CT.gov Metformin+ Drospirenone/ethinylestradiol30µg and Flow-mediated Dilation in Polycystic Ovary Syndrome | — | Unknown | — | — | — |
NCT01519401CT.gov Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome. | — | Completed | — | — | — |
NCT00442689CT.gov Metabolic Syndrome in PCOS: Precursors and Interventions | — | Completed | — | — | — |
NCT00842140CT.gov Safety of Hormonal Contraceptives Therapies in Polycystic Ovary Syndrome (PCOS) Women | — | Completed | — | — | — |
NCT00593294CT.gov Oral Contraceptive and Cardiovascular Risk in PCOS | — | Completed | — | — | — |
NCT00640224CT.gov Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study | — | Completed | — | — | — |
NCT01511822CT.gov Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Polycystic Ovary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ethinyl Estradiol (this asset) | Ege University | Approved | BBB · 76 |
| Human Chorionic Gonadotropin | Eman Basuni Ebrahim Mowad | P4 | BBB |
| Liraglutide | Peking University Third Hospital | P4 | BBB |
| Semaglutide | Methodist Health System | P4 | BBB |
| Drospirenone | Ege University | P4 | BBB |
| Follitropin Beta | Universitair Ziekenhuis Brussel | P4 | BBB |
| Glucophage | Near East University, Turkey | P4 | BBB |
| Vitamin D | Yale University | P4 | BBB |
| Cetrotide | Ahmed Saad | P4 | BBB |
+41 more in the Polycystic Ovary Syndrome cohort
Other indications for Ethinyl Estradiol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infertility Disorder | — | P4 | B · 63 |
| Migraine Disorder | — | P3 | B · 63 |
| Chronic Pain Syndrome | — | P4 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ethinyl Estradiol in Polycystic Ovary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ethinyl-estradiol-polycystic-ovary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →